The DEA Wants Five More Tryptamines in Schedule I. Comments Close October 23
A proposed rule would place five tryptamines into Schedule I. It is the second attempt at the same action, and comments close October 23.
Read More
9 Things Buyers Check Before Acquiring a Ketamine Clinic
Diligence is unglamorous. Nine things acquirers actually look at in a ketamine practice, from accrual books and payer contracts to outcomes data and chair utilization.
Read More
Whether the Ketamine Experience Matters Depends on Which Questionnaire You Use
A new letter in npj Mental Health Research argues a 2024 meta-analysis compared ketamine and psilocybin with different instruments. Across the same ketamine studies, one scale explains 3 percent of outcomes and another explains 15 percent.
Read More
Dissociation Was Tied to Better Esketamine Outcomes in a Small Study
Higher dissociation scores went with better depression outcomes on subcutaneous esketamine, with derealization driving the difference. The study was small, open label and exploratory.
Read More
The Ketamine Clinics Winning Psychiatrist Referrals Are the Ones Sending Scores Back
Collecting PHQ-9 scores is common. Being able to state a response rate, and send it back to the referring clinician, is not. That gap is where referrals, payer talks and exit value live.
Read More
6 Regulatory Deadlines Ketamine Clinics Should Have on the Calendar
From FDA's October 5 psychedelics docket to the DEA telehealth expiration and Medicare's 2027 in-person rule, six dates every ketamine clinic should plan around.
Read More
Two Ketamine Brain Studies Point to the Same Moment: The Day After the Infusion
Oxford found ketamine quieted the habenula 24 hours after infusion. A Texas A&M analysis linked 24-hour brain changes in older veterans to day-7 improvement.
Read More
Medicaid Is the Largest Behavioral Health Payer. A New Report Asks What Happens Next
A Center for Health Care Strategies report examines how psychedelic-assisted therapy could reach Medicaid. Some states already cover off-label IV ketamine.
Read More
Pharma Is Now Bidding on the Keywords Your Clinic Buys
Johnson & Johnson, Mindbloom and BetterU are all bidding on generic psychedelic search terms. Here is what that does to a local clinic's acquisition cost.
Read More
A Controlled Trial Finally Tested Ketamine in the Patients Clinics Screen Out
Bipolar patients are routinely screened out of ketamine treatment over mania risk. A midazolam-controlled trial in JAMA Psychiatry finally tested the question.
Read More